MarginsXMarginsX
Home › Markets › Health Care › OGEN

Oragenics Inc. (OGEN)

OGEN trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.1980
-1.49% on the day
Market cap
$893K
Nano cap
Revenue · 2023
$38K
-71.4% on 2022
Net income · 2023
-$20.7M
-54858.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/1174940/000149315225010389/0001493152-25-010389-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.

Profile

FieldValue
TickerOGEN on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001174940

Financials · 2023

LineValue
Revenue$38K
Net income-$20.7M
Operating income-$20.9M
Net margin-54858.1%
Operating margin-55519.9%
Revenue growth-71.4%
Cash$3.5M
Total assets$5.0M
P/E (computed)Net income was not positive
P/S (computed)23.7×

Warning signs

Cash runway
2.9 months
$2.2M cash at September 30, 2026
Share count, 1 year
+8.2%
2025-11-06 to 2026-11-11 · +5168.1% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
-$197
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt regarding our ability to continue as a going concern."
10-Q 2026-11-12
Cash and burn$2.2M cash; operating cash flow -$2.3M a quarter.Report 2026-09-30
Shares outstanding4,511,957 (2026-11-11); 4,168,223 a year earlier; 2,569,385 three years earlier. 3y figure adjusted for splits (1-for-30 overall).Cover page 2026-11-11
Reverse splits, 3 years1; latest 1-for-30 on 2025-06-03Source 2025-06-03
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-01-22
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-08-28
AuditorCherry Bekaert LLP, Tampa, Florida, United StatesPCAOB Form AP 2026-03-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $197 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$2.6M-$2.0M$2.2M$397KNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$2.5M-$2.2M$3.9MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2026
2026-03-31
Not filed-$2.2M-$2.2M$6.1M$56KNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
Not filed-$2.3M-$2.8M$4.4M$227KNeeds four quarters10-K 2026-03-16
Q3 2025
2025-09-30
Not filed-$3.1M-$3.0M$11.4M$395KNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$2.3M-$1.3M$2.0M$3.0MNeeds four quarters10-Q 2026-11-12
Q1 2025
2025-03-31
Not filed-$2.2M-$2.1M$3.4M$2.6MNeeds four quarters10-Q 2026-11-12
Q4 2024
2024-12-31
Not filed-$3.3M-$2.0M$865K$329KNeeds four quarters10-K 2026-03-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-42.9%
1 month-55.6%
3 months-62.3%
Year to date-74.4%
1 year-82.5%
From 52-week high-82.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MTNBMatinas Biopharma Holdings Inc.$0.9270+3.00%$908K
SPRCSciSparc Ltd.$0.3307-10.62%$815K
GOVXGeoVax Labs Inc.$2.02+18.48%$1.1M
BDRXBiodexa Pharmaceuticals plc American Depositary Shs$2.24-6.28%$1.2M
ELABPMGC Holdings Inc.$1.66+5.06%$1.3M
KAPAKairos Pharma Ltd.$0.4069-10.30%$1.4M
APVOAptevo Therapeutics Inc.$0.5486-7.66%$1.5M
LABTLakewood-Amedex Biotherapeutics Inc.$0.2194-22.31%$520K

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier